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Abstract
Background: We have previously demonstrated that immune modulation can be accomplished by administration
of gene silenced dendritic cells (DC) using siRNA. In this study, we demonstrate the therapeutic utilization of
shRNA-modified DC as an antigen-specific tolerogenic vaccine strategy for autoimmune arthritis.
Methods: A shRNA that specifically targets IL-12 p35 was designed and cloned into a plasmid vectors (IL-12
shRNA). Bone marrow-derived DC from DBA/1 mice were transfected with the IL-12 shRNA construct in vitro. Mice
with collagen II (CII)-induced arthritis (CIA) were treated with the modified DCs expressing the shRNA. Recall
response and disease progression were assessed.
Results: After gene silencing of IL-12 in DC, DC were shown to selectively inhibit T cell proliferation on recall
responses and in an MLR. In murine CIA, we demonstrated that administration of IL-12 shRNA-expressing DC that
were pulsed with CII inhibited progression of arthritis. The therapeutic effects were evidenced by decreased clinical
scores, inhibition of inflammatory cell infiltration in the joint, and suppression of T cell and B cell responses to CII.
Conclusion: We demonstrate a novel tolerance-inducing protocol for the treatment of autoimmune inflammatory
joint disease in which the target antigen is known, utilizing DNA-directed RNA interference.
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Background
Rheumatoid Arthritis (RA) is a chronic autoimmune
condition characterized by non-specific, usually sym-
metric inflammation of the peripheral joints, resulting in
progressive destruction of articular and periarticular
structures. One of the hallmark pathologies of RA is
thickening and swelling of synovial tissue, primarily as a
result of T cell production of inflammatory factors [1,2].
Up to 50% of the infiltrating leukocytes in the synovium
are T-lymphocytes, primarily CD4
+ T cells with an acti-
vated/memory phenotype [3-5], expressing a Th1 bias
[5,6]. Clinical treatment of RA involves initiating Disease
Modifying Anti-Rheumatic Drug (DMARD) therapy
early following diagnosis with subsequent optimization
of drug therapy in order to have a greater beneficial
impact on disease outcome [7]. DMARDs are antigen-
nonspecific in their activities and include known
immune suppressants such as methotrexate, lefluno-
mide, hydroxychloroquine, sulfasalazine, and corticoster-
oids. The introduction of “biological DMARDs” such as
Embrel and Remicade led to a major improvement in
quality of life of RA patients, however these drugs are
limited by cost, non-cure of the disease, and adverse
effects such as heightened risk of infection [8,9].
Despite promising animal data, to date, antigen-speci-
fic treatments of RA have not been clinically successful.
While approaches such as intravenous immunoglobulin
[10], oral tolerance [11,12], and tolerogenic peptide ther-
apy [13] have demonstrated promising results in various
models, clinical trials have yielded results that are med-
iocre at best. Dendritic cell (DC) therapy is considered
one of the most potent means of antigen-specifically
modulating an immune response given the innate pro-
pensity of DC to either activate or inhibit adaptive
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Provenge as an antigen-specific immunotherapy for
prostate cancer attests to the ability of this approach to
be translated clinically [18]. Although exceptions exist,
generally speaking, in immature states, DC act primarily
as tolerogenic cells, caused deviation of Th1 immunity,
as well as generation of T regulatory cells [19,20],
whereas mature DC are immune stimulatory. We have
previously applied these findings in the animal model of
RA, collagen induced arthritis (CIA) to demonstrate that
DC made immature by treatment with a synthetic RelB
inhibitor prevented disease progression [21]. These find-
ings were confirmed in subsequent studies in which we
generated “artificially immature” DC using siRNA to
silence the markers of maturation, CD40, CD80, and
CD86. When these DC were pulsed with collagen II, the
autoantigen implicated in CIA, we observed regression
of disease [22,23]. Given that T cell activation involves
not only cell surface costimulatory molecules but also
cytokines, we chose to examine whether silencing of the
cytokine IL-12 on DC would also induce a pro-tolero-
genic activity.
The cytokine IL-12 is a soluble factor used by the DC
to guide differentiation of naïve T cells into a Th1, cyto-
toxic/inflammatory state [24-26]. Several studies suggest
that IL-12 is associated with autoimmunity in a patholo-
gies such as arthritis [27,28], diabetes [29,30], multiple
sclerosis [31,32], and thyroiditis [33,34]. Therefore, a
method of selectively inhibiting the IL-12 production at
the level of the DC may be an ideal mechanism of
immunotherapy for autoimmune diseases. Supporting
the importance of IL-12 in DC mediated immune mod-
ulation, we have previously demonstrated that siRNA-
mediated silencing of the IL-12p35 gene on DC causes
immune deviation on recall response towards a Th2-like
profile [35]. In the current study we silenced the IL-
12p35 gene on DC that were pulsed with collagen II
protein. We demonstrated that administration of this
antigen specific “tolerogenic vaccine” was capable of
inducing a Th2-biased recall response, as well as sup-
pression of pathology in the CIA model. These findings
m a yb es u p p o r t i v eo ff u t u r ec l i n i c a ld e v e l o p m e n tu s i n g
IL-12p35 silenced antigen-pulsed DC.
Methods
Animals
Male DBA/1 LacJ and BALB/c mice (The Jackson Labora-
tories, Bar Harbor, ME), 5 weeks of age, were kept in fil-
ter-top cages in the Animal Care and Veterinary Services
Facility at the University of Western Ontario according to
the Canadian Council for Animal Care Guidelines. Mice
w e r ef e db yf o o da n dw a t e ra n da l l o w e dt os e t t l ef o r2
weeks before initiation of experiments, which had ethical
approval from the university review board.
CIA model
DBA/1 LacJ mice, 7 weeks of age, were intradermally
immunized (Day 0) at several sites into the base of the
tail with 200 μg of bovine type II collagen (CII) (Sigma-
Aldrich, St. Louis, MO) dissolved in 100 μlo f0 . 0 5M
acetic acid and mixed with an equal volume of complete
Freund’s adjuvant (CFA) (Sigma). CII was dissolved at a
concentration of 2 mg/ml by stirring overnight at 4°C.
On day 21 after priming, the mice received an intraperi-
toneal booster injection with 200 μg of CII in the equal
volume (100 μl) of PBS. Mice were examined visually
three times per week for the appearance of arthritis in
the peripheral joints, and arthritis score index for dis-
ease severity was given as follows: 0 - no evidence of
erythema and swelling; 1 - erythema and mild swelling
confined to the mid-foot (tarsals) or ankle joint; 2 -
erythema and mild swelling extending from the ankle to
the mid-foot; 3 - erythema and moderate swelling
extending from the ankle to the metatarsal joints; 4 -
erythema and severe swelling encompass the ankle, foot,
and digits. Scoring was done by two independent obser-
vers, without knowledge of the experimental and control
groups.
DC cultures
At Day 0, bone marrow cells were flushed from the
femurs and tibias of DBA/1 LacJ mice, washed and cul-
tured in 6-well plates (Corning, NY) at 4 × 10
6 cells/
well in 4 ml of complete medium (RPMI 1640 supple-
mented with 2 mM L-glutamine, 100 U/ml penicillin,
100 μgo fs t r e p t o m y c i n ,5 0μM 2-ME, and 10% FCS (all
from Life Technologies, Ontario, Canada) supplemented
with recombinant GM-CSF (10 ng/ml; PeproTech,
Rocky Hill, NJ) and recombinant mouse IL-4 (10 ng/ml;
PeproTech). All cultures were incubated at 37°C in 5%
humidified CO2. Non-adherent cells were removed after
48 h of culture (Day 2) and fresh medium was added
every 48 h.
shRNA expressing vectors and transfection
siRNA sequences were selected according to the method
of Elbashir SM et al. [36]. The siRNA sequence specific
for IL-12p35 (AACCUGCUGAAGACCACAGAU) was
selected and cloned into Psilencer 3.1 vector (Ambion,
Austin, TX) which expresses short hairpin RNA
(shRNA) under the control of the mouse U6 promoter,
using the method described by the supplier of the vec-
tor. IL-12 shRNA was sequenced and prepared in a
large scale for in vitro and in vivo study. Gene silencing
was examined with DC. DC were generated from bone
marrow progenitor cells as previously described [35].
Transfection of DC was conducted as described pre-
viously [36]. 24 h before transfection (day 4), DC were
plated to be 60-90% confluent on the day of
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GenePORTER reagent (Gene Therapy Systems, San
Diego, CA) were separately diluted with serum-free
m e d i u mR P M I1 6 4 0u s i n g1 / 2o ft h et r a n s f e c t i o n
volume (125 μl). The diluted DNA was added to the
diluted GenePORTER reagent, mixed rapidly and incu-
bated in total volume of 250 μl of the medium at room
temperature for 45 min. The culture medium from the
DC was aspirated, and the DNA-GenePORTER mixture
was added carefully to the DC. Mock controls were
transfected with 3 μl of the GenePORTER reagent
alone. After 4-h incubation, an equal volume of RPMI
1640 (250 μl) supplemented with 20% FCS was added to
the cells. 48 h after the start of transfection (day 7), DC
were washed and pulsed with 10 μg/ml of CII for 24 h.
At day 8, DC were then activated with LPS/TNF-a for
additional 24 h. 7 days before and/or 12 days after prim-
ing with CII, different groups of mice with 6 animals per
group were i.p. injected with shRNA-transfected or con-
trol DC at a dose of 5 × 10
6 cells per mouse.
RT-PCR
Total RNA was extracted from cells using Trizol (Invi-
trogen). 3 μg total RNA was used to synthesize the
cDNA with oligdT and reverse transcriptase (Invitrogen)
in 20 μl reaction volume. Primers used for the amplifi-
cation of murine IL-12, IFNg,I L - 2 ,I L - 4 ,I L - 1 0a n d
GAPDH were as follows [37]: IL-12, 5’- CTT GCC CTC
CTA AAC CAC CTC AGT-3’ (forward) and 5’- CCA
CCA GCA TGC CCT TGT CTA-3’ (reverse); IFNg,5 ’-
CAC GGC ACA GTC ATT GAA AGC CTA-3’ (for-
ward) and 5’- TGA GGC TGG ATT CCG GCA ACA
GCT-3’ (reverse);
IL-2, 5’- ACA TTG ACA CTT GTG CTC CGT GTC-
3’ (forward) and 5’- TTG AGG GCT TGT TGA GAT
GAT GCT-3’ (reverse); IL-4, 5’- AGC TAG TTG TCA
TCC TGC TCT TCT-3’ (forward) and 5’- CGA GTA
ATC CAT TTG CAT GAT GCT-3’ (reverse); IL-10, 5’-
GAA GAC AAT AAC TGC ACC CAC TTC-3’ (for-
ward) and 5’- ATG GCC TTG TAG ACA CCT TGG
TCT-3’ (reverse); GAPDH, 5’-TGA TGA CAT CAA
GAA GGT GGT GAA-3’ (forward) and 5’-TGG GAT
GGA AAT TGT GAG GGA GAT-3’ (reverse).
Polymerase chain reaction (PCR) was performed in a
25 μl of reaction volume containing 0.2 μmol/L primers,
1 U Taq DNA polymerase under the following condi-
tions: 95°C for 30 s, 58°C for 30 s, and then 72°C for 30
s (30 cycles). PCR products were visualized with ethi-
dium bromide on 1.5% agarose gel.
Mixed leukocyte reaction (MLR)
At day 5 of culture, bone marrow-derived DC from
DBA/1 LacJ mice were transfected with IL-12 and
s c r a m b l e ds i R N A so rm o c k - t r a n s f e c t e df o l l o w e db y
activation with LPS/TNF-a. Activated DC were irra-
diated (3,000 rad) and seeded in triplicate in a flat-bot-
tom 96-well plate (Corning) for use as stimulator cells.
Spleen T cells from BALB/c mice were isolated by gra-
dient centrifugation over Ficoll-Paque (Amersham Phar-
macia Biotech, Quebec) and added as responders (5 ×
10
5 cells/well). The mixed lymphocytes were cultured at
37°C for 72 h in 200 μlo fR P M I1 6 4 0s u p p l e m e n t e d
with 10% FCS, 100 U/ml of penicillin, and 100 μg/ml of
streptomycin and pulsed with 1 μCi/well of
3H-labelled
thymidine (Amersham Pharmacia Biotech) for the last
16 h of culture. Finally, cells were harvested onto glass
fiber filters, and the radioactivity incorporated was
quantitated using a Wallac Betaplate liquid scintillation
counter (Beckman, Fullerton, CA). Results were
expressed as the mean counts per min of triplicate cul-
tures ± SEM.
Proliferation assays
T cell proliferative responses to CII in subsequent groups
of mice were measured with a standard microtiter assay.
Following CII immunization, the proliferative responses
could be detected for several weeks. Immune cells from
either draining lymph node or spleen T cells collected
from the mice treated with CII and IL-12 silenced DC or
control DC, at 5 × 10
5/well were seeded to a 96-well flat-
bottom microtiter plate (Corning) in triplicates and
mixed with serial dilutions of CII with concentrations
ranging from 5 to 50 μg/well. Following a 72 h incuba-
tion, 1 μCi of [
3H] thymidine (Amersham) was added to
each well for 16 h. Using an automated cell harvester, the
cells were collected onto glass microfiber filter, and the
radioactive labeling incorporation was measured by a
Wallac Betaplate liquid scintillation counter.
Anti-CII antibody measurement
CII-specific Abs were evaluated using a standard indir-
ect ELISA in which 500 ng of CII was absorbed to each
well of a 96-well microtitre plate. Following blocking
and washing steps, serial dilutions of immune mouse
serum were added to the appropriate wells in duplicates
and incubated overnight at 4°C. Dilutions of serum were
1:100-1:100,000. To develop the ELISA, horseradish per-
oxidase-conjugated goat anti-mouse IgG Fc and ortho-
phenylenediamine dihydrochloride substrate buffer
(Sigma) were used. The OD of each well was measured
at a wavelength of 490 nm in an ELISA plate reader.
Cytokine quantification
Mock or shRNA-transfected DC of DBA/1 LacJ origin
were cultured with the allogeneic (BALB/c) T cells or
alone for 48 h. The supernatants were collected and
assessed for DC cytokines (IL-10 and IL-12) and T cell
cytokines (IFN-g and IL-4) by ELISA. Cytokine-specific
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cytokine concentrations in culture supernatants accord-
ing to the manufacturer’s instructions using a Bench-
mark Microplate Reader (Bio-Rad, Hercules, CA).
Histology
Paws from experimental and control groups of freshly
dissected mice were removed and joint tissues were
immersion-fixed for 4 day in 10% (wt/vol) neutral buf-
fered formalin in 0.15 M PBS (pH 7.4). After decalcifica-
tion by immersing in Decalcifier I solution (Winnipeg,
Canada) overnight and subsequent dehydration in a gra-
dient of alcohols, tissues were rinsed in running water.
The specimens were processed for paraffin embedding
in paraplast (BDH, Dorset, UK) as routine procedure.
Serial paraffin sections throughout the joint were cut at
5-μm thickness on a microtome, heated at 60°C for 30
min, and deparaffinized. Hydration was done by trans-
ferring the sections through the following solutions: tri-
ple to xylene for 6 min, and then for 2 min to 100%
ethanol twice, 95% ethanol, and 70% ethanol. Sections
were stained with H&E and mounted on glass slides.
Intracellular cytokine staining and flow cytometry
Transfected DCs were treated with 20 ng/ml phorbol
myristate acetate and stained with FITC-conjugated IL-
12. Ig of the same isotype was used as controls. Flow
cytometry analysis was performed in a FACScan II (Bec-
t o nD i c k i n s o n ,S a nJ o s e ,C A -B D )s y s t e mu s i n gF A C S -
Diva software (BD).
Statistical analysis
Data are expressed as mean ± SEM. Differences between
different groups of mice were compared using the
Mann-Whitney U test for nonparametric data. A P
value less than 0.05 was considered significant.
Results
Silencing DC with IL-12 shRNA
Silencing of IL-12p35 on bone marrow derived DC was
previously performed by our group using presynthesized
siRNA [35]. Although this approach is widely used, one
disadvantage is the relatively low efficacy due to consump-
tion of the exogenously administered siRNA. An alterna-
tive approach would be to induce the cell to produce
siRNA endogenously. One way of achieving this is using
so-called DNA-directed RNAi (ddRNAi), which utilizes a
DNA construct expressing double stranded RNA. Accord-
ingly we transfected DC with a vector comprising a hair-
pin loop of siRNA (shRNA), driven by U6 promoter.
We determined the gene silencing efficacy of IL-12
shRNA on DC by RT-PCR (Figure 1A). IL-12 shRNA
reduced IL-12 expression on DC by 3-fold as compared
with control. The gene silencing effect of IL-12 shRNA
was further confirmed at the protein level by intracellu-
lar staining with anti-IL-12 antibody using flow cytome-
try (Figure 1B). These data suggest feasibility of specific
gene silencing in DC using the shRNA approach.
In vitro immune modulation by IL-12 shRNA
IL-12 is an important cytokine for the interaction of DC
and T cells. IL-12 secreted by DC controls T helper cell
deviation. Thus, we assessed whether silencing of IL-
12p35 using shRNA would alter the ability of the DC to
modulate a Th1 to Th2 shift. Using an allogeneic system,
we co-cultured C57/BL6 DC, treated with IL-12 shRNA,
together with responder BALB/c T cells. This resulted in a
predominant Th2 cytokine profile (e.g. high IL-4, low
IFN-g), as compared to the co-culture with DC treated
with control shRNA which possessed a Th1 profile (Figure
2A). We next tested the antigen presentation capacity of
DC after gene silencing of IL-12 by quantifying prolifera-
tive response of the BALB/c T cells reacting against con-
trol and IL-12 silenced C57BL/6 DC. Figure 2B showed
Figure 1 Gene silencing of IL-12 shRNA on DC.( A)G e n e
silencing efficacy of IL-12 shRNA was determined by RT-PCR. DC
were cultured for 4 days as described in the methods. On day 5,
10
6 DC were transfected with 2 μg of IL-12 shRNA using
GenePORTER reagent. One day after transfection, DC were harvested
and mRNA detected. (B) Gene silencing efficacy of IL-12 shRNA was
determined by flow cytometry. DC were transfected as above and
collected 48 h after transfection. DC were intracellular stained with
FITC labeled anti-IL-12 antibody and followed by flow cytometry
analysis. The data presented one of three independent experiments.
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the DC in which IL-12 gene is silenced. These data suggest
that IL-12 not only plays a role in production of IFN-g and
IL-4, but also is involved in stimulation of T cell prolifera-
tion by allogeneic DC. Accordingly, we sought to deter-
mine whether DC modulated in this manner may be
useful for modulating an immune response in vivo in an
autoimmune disease model.
Inhibition of CIA by treatment with IL-12 shRNA-
transfected DC
The CIA model of RA is an ideal system for assessment of
therapeutics based on the fact that it displays similar
onset, progression, and pathology to clinical RA. Impor-
tantly, the autoantigen in CIA is molecularly defined CII
and T cell responses to this protein are essential for dis-
ease continuation [38]. We have previously demonstrated
that silencing expression of IL-12p35 in DC leads to in
vivo immune modulation of T cell response to a nominal
antigen KLH [35]. In the previous study we utilized pre-
synthesized siRNA, and we did not assess ability to inhibit
immunity in a therapeutic model. In this study, we used a
clinically relevant model of autoimmune arthritis and eval-
uated two treatment protocols. When, 12 days after prim-
ing with CII, DBA/1 mice were administered a single
injection of IL-12 shRNA-transfected DC pulsed with CII,
an inhibition of arthritis clinical score had been observed
11 days after arthritis onset as opposed to control-treated
mice receiving DC that were not gene-silenced for IL-12
(Figure 3A). The average clinical scores per affected paw
in the control group were two times higher than that in
the treatment group. To confirm the therapeutic effects by
IL-12 silenced DC, we further sought to examine micro-
scopic histological differences induced by treatment of
CIA mice with the IL-12-silenced and CII-pulsed DC.
Accordingly, animals treated with IL-12 shRNA-trans-
fected DC or control DC were sacrificed 4 weeks following
onset of arthritis and joints were examined by serial sec-
tioning. We observed that control mice possessed severe
bone erosion, pannus formation, and synovitis (Figure 3B).
A marked neutrophilic and mononuclear cell infiltration
was seen. In contrast, joint histology of the IL-12-silenced
DC treated mice revealed markedly attenuated morpholo-
gical changes and cellular infiltration, and the preservation
of normal cartilage structure (Figure 3C). The histological
verification of the arthritis clinical score strongly suggests
that the IL-12 silenced and CII-pulsed DCs can serve as a
potent tolerogenic vaccine that might be useful for the
treatment of autoimmune arthritis.
While the protocol above was therapeutic in the sense
that the intervention was given after initiation of immune
response, we chose to determine whether the combination
of a prophylactic (i.e. 7 days before priming with CII) and
the therapeutic IL-12-silenced DC injection resulted in
additive or synergistic inhibition of arthritis development.
Using this combination we observed a lower severity of
arthritis, as compared to a single injection protocol (Figure
3D). Furthermore, the control DC group had higher aver-
age clinical score than experimental group ranged from 2-
fold to more than 4-fold depending on the timepoint of
assessment. This suggests that a combination of cellular
vaccine strategies could lead to additive anti-arthritis effects.
IL-12 shRNA silenced DC inhibited CII-specific T cell
response in arthritic mice
It has been previously described that immune modula-
tion by administration of IL-10-treated DC can inhibit
Figure 2 Immune modulation by IL-12 shRNA silenced DC.( A)
IL-12 silenced DC promote Th2 cytokine production. Control and
siRNA-treated DC were cultured with allogeneic T cells for 3 days.
Co-cultured T cells were harvested and gene expression of IFNg, IL-
2, IL-4 and IL-10 were detected by RT-PCR. (B) DC silenced with IL-
12 shRNA inhibited allogeneic T cell proliferation. DC (1 × 10
5 cells/
well) were co-cultured with allo-T cells (5 × 10
5 cells/well) in 96-well
plate for 72 h. 1 μCi/well of
3H-labelled thymidine was added to the
culture for the last 16 h of culture and proliferation was assessed by
scintillation counting. Results were expressed as the mean counts
per min of triplicate cultures ± SEM. * = P < 0.05.
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long-term effects of immune modulation with inhibi-
tory DC have not been reported. Here, we have mea-
sured CII-specific T cell recall responses after arthritis
development in mice treated with IL-12 shRNA-trans-
fected DC pulsed with CII. Four-weeks after arthritis
onset, we extracted lymph node and spleen T cells
from correspondent group of animals in 4 weeks fol-
lowing the first signs of arthritis. A profound suppres-
sion of response to CII was observed in T cells
derived from both lymph node (Figure 4A) and spleen
(Figure 4B) sources in the mice treated with IL-12
siRNA.
Reduced threshold for inhibition of antibody response to
CII in arthritis mice
The importance of CII-specific antibodies in develop-
ment of CIA pathology is well-known [21]. However,
control of antibody responses by DC has not been pre-
viously examined in a therapeutic sense. Tolerogenic
DC may directly block antibody production through
inhibition of BlyS and APRIL, factors which the DC use
to directly induce Ig production and class switching in B
cells [40,41]. Alternatively, tolerogenic DC may indir-
ectly prevent antibody production through the inhibition
of T cell helper function. Here, we assessed antibody
responses to CII in animals 4 weeks after arthritis onset.
Using a titration experiment, we compared the serum
levels of anti-CII Ig from control mice with CIA mice
treated with single injection of IL-12-silenced/CII-pulsed
DC twice, before and after CII administration. CII-speci-
f i ca n t i b o d yr e s p o n s ew a si n h i b i t e db yb o t ht h es i n g l e
injection (Figure 5A) and by the two injections of the
IL-12 silenced DC (Figure 5B). This indicates that the
IL-12 shRNA-transfected DC represent an immunomo-
dulatory therapeutic strategy since they are not only
involved in suppression of T cell responses but also in
antibody production.
Figure 3 Inhibition of clinical development of CIA in mice
injected with IL-12 shRNA-transfected DC.( A) Index of disease
severity of joint after single DC treatment. 12 days after intradermal
challenge with CII (200 μg per mouse), DBA/1 LacJ mice were
treated with one i.p. injections of 5 × 10
6 IL-12-silenced DC pulsed
with CII (10 μg/ml). Control siRNA -transfected DC pulsed with CII
served as a control. All mice were i.p. boosted with the same dose
of CII 21 day after priming with the antigen. The animals were
observed for 4 weeks since arthritis onset. Each limb was graded on
a scale from 0 to 4 and the average clinical score per affected paw
was calculated. Each point denotes the score of 5 mice in each
group. Results represent 1 of 3 experiments. * = P < 0.05 versus
control DC. (B) Histological sections of joints from arthritis mice
injected with control DC. H&E stained sagittal sections of proximal
interphalangeal joints. Sections from control mice show widespread
inflammation cell infiltration, mild edema and congestion. Cartilage
surface became uneven due to soft bone damage. (C) Histological
sections of joints from arthritis mice injected with IL-12 shRNA-
transfected DC. The majority of sections from animals treated with
single injection of IL-12-silenced DC pulsed with CII do not show
monocyte infiltration, edema and congestion. Cartilage surface
appears smooth. Original magnification × 100. Results represent 1 of
15 mice. (D) Index of disease severity of joint after two DC
treatments. 7 days before and 12 days after intradermal challenge
with CII (200 μg per mouse), DBA/1 LacJ mice were treated with i.p.
injections of 5 × 10
6 IL-12-silenced DC pulsed with CII (10 μg/ml).
Mock-transfected DC pulsed with CII served as a control. All mice
were i.p. boosted with the same dose of CII 21 day after priming
with the antigen. The animals were observed for 4 weeks since
arthritis onset. Each limb was graded on a scale from 0 to 4 and the
average clinical score per affected paw was calculated. Each point
denotes the score of 5 mice in each group. Results represent 1 of 3
experiments. * = P < 0.05 versus control DC.
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We previously demonstrated that silencing IL-12 resulted
in immune deviation and modulation in vitro and in vivo
[21]. However, to date, therapeutic utilization of shRNA-
transfected DC has not been performed in arthritis. In
this study, we have reported that silencing the Th1-indu-
cing cytokine IL-12 with DNA-directed RNA interference
(ddRNAi) in the form of shRNA leads to a potent Th2
d e v i a t i o nt h a tc u l m i n a t e si ni n h i b i t i o no fC I A ,t h em u r -
ine model of rheumatoid arthritis. This model is optimal
for antigen-specific immune modulation since: 1) disease
is associated with a defined antigen, CII [42]; 2) a defined
cytokine response, which is known to be IL-12-depen-
d e n t ,l e a d i n gt oI F N - g-driven activation of macrophages
and synoviocytes, and is causative in the inflammatory
lesions that appear [40]; and 3) the CIA model is modifi-
able by exogenous manipulations [43]. Our experimental
protocols consisted of administering CII-pulsed IL-12-
silenced DC at day -7, and/or day 12 following the first
CII challenge. These protocols were used to assess both
prophylactic and therapeutic effects of the tolerogenic
IL-12 shRNA-transfected DC.
Mature myeloid DC possess high expression of MHC
class II molecules (signal 1), costimulatory molecules
(signal 2) and IL-12 (signal 3). Signals 1 and 2 stimulate
T cell activation, while signal 3 polarizes T-helper (Th)
differentiation. Therefore, immune modulation can be
achieved through inhibition of immune molecules in DC
by various blockades such as antibodies [44], fusion pro-
teins [45,46] or antisense oligonucleotides [47], and
pharmacological agents [21].I nc o m p a r i s o nw i t ht h e s e
previously used blocking methods, silencing gene
Figure 4 T cell recall responses to CII in arthritis mice injected
with IL-12 shRNA-transfected DC. Experimental and control
groups of mice were treated with two injections of IL-12-silenced
DC as described in the legend to Figure 3. At the end of clinical
assessment of CIA development, the mice were sacrificed and T
cells from lymph nodes (A) and spleens (B) were isolated. A CII-
specific response from different group of animals was performed by
proliferation, as described in Materials and Methods. Lymphocytes
were restimulated in vitro with different concentrations of CII, KLH
or PBS alone and a
3H-labelled thymidine incorporation was
measured. Results represent 1 of 3 similar experiments (n = 4 per
group/experiment). * = P < 0.05 versus control PBS-treated DC.
Figure 5 Inhibition of CII-specific antibody production in
arthritis mice following injections with IL-12 shRNA-transfected
DC. Blood was taken 4 weeks after arthritis onset from experimental
and control groups of mice treated with one (A) or two (B)
injections of IL-12-silenced DC, as described in the legend to the
Figure 2. Serum levels of anti-CII immunoglobulin Fc were
determined using ELISA. Results show average levels of antibodies
expressed as OD (n = 4 per group/experiment). * = P < 0.05 versus
control shRNA-transfected DC.
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Page 7 of 10expression through ddRNAi may prove superior to con-
ventional gene or antibody blocking approaches for the
following reasons: 1) blocking efficacy is potent [48]; 2)
targeting gene expression is specific to one nucleotide
mismatch [49]; 3) inhibitory effects can be passed for
multiple generations to daughter cells [50]; 4) in vitro
transfection efficacy is high [35] and can be expressed in
a stable manner [51]; 5) in vivo use may be more practi-
cal and safer than antibody approaches due to lower
concentrations needed for silencing, and lack of neutra-
lizing antibody production; 6) tissue or cell specific gene
targeting is possible using specific promoter vectors
[52,53] or specific antibody conjugated liposomes
[27,54]; 7) simultaneously targeting multiple genes or
multiple exons silencing is possible for increasing effi-
cacy [55]. Clinical efficacy of ddRNAi has been recently
demonstrated in AIDS-related lymphoma patients who
received viral-vector transfected autologous CD34 cells,
in which it was demonstrated that the cells and their
progeny expressed the shRNA for at least two years
from a single ex vivo transfection treatment [56].
In contrast to other methods of DC modulation,
induction of RNAi in this cell population offers an
approach to specifically modify the immune-regulating
abilities of DC. In our first description of shRNA-
manipulated DC, we demonstrated that silencing of IL-
12p35 is sufficient to induce a DC population that sti-
mulates Th2 immune responses in vitro and in vivo
[35]. Since DC can be pulsed with antigenic peptides or
mRNA ex vivo, the shRNA-modification of this cell type
offers the ability to generate vaccines not only for stimu-
lation but also for inhibition of immunity. Subsequent to
our initial study, two other groups have reported utiliza-
tion of RNAi in DC. Laderach et al [57] reported speci-
fic and efficient silencing the NF-B gene in human
monocyte-derived DC using siRNA transfected via elec-
troporation. This study was particularly interesting since
it clearly demonstrated the ability of siRNA to study the
specific functions of subunits comprising multimeric
transcription factors [57]. Silencing of DC cell lines
u s i n gs h R N Aw a su s e db yW o n ge ta lt os i l e n c et h e
Plexin A1 gene, demonstrating that this neuronal-speci-
fic protein is critical in DC-T cell interactions [58].
More recently, we induced transplant tolerance through
gene silencing of RelB [59]. These reports indicate the
utility of RNAi for immunological and molecular inves-
tigations of DC. Despite the success of silencing DC by
siRNA, several key issues of gene silencing in DC
remains undetermined, such as siRNA delivery methods,
persistence of silencing efficacy, and multiple gene silen-
cing. We demonstrate that RNA interference can be
accomplished in DC either by transient delivery of pre-
synthesized siRNA or by transfection of plasmid
encoding shRNA. Utilizing shRNA, the gene silencing
efficacy can last at least up to the end point of DC cul-
ture [60].
Conclusion
These results serve as a proof-of-principle study, illus-
trating that DNA-directed RNA interference in the form
of shRNA can be used efficiently, and rapidly for pro-
duction of tailor-made tolerogenic DC that are primed
with specific antigen for a cellular “tolerogenic vaccine”.
With the identification of a plethora of novel immune
stimulatory genes, it raises the possibility of using
ddRNAi gene-silenced tolerogenic DC for individualized
therapy of autoimmune diseases.
Abbreviations
siRNA: Small interfering RNA; shRNA: Short hairpin RNA; ddRNAi: DNA-
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